These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 1648919)

  • 1. SK&F 96067 is a reversible, lumenally acting inhibitor of the gastric (H+ + K+)-ATPase.
    Keeling DJ; Malcolm RC; Laing SM; Ife RJ; Leach CA
    Biochem Pharmacol; 1991 Jun; 42(1):123-30. PubMed ID: 1648919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properties of the reversible K(+)-competitive inhibitor of the gastric (H+/K+)-ATPase, SK&F 97574. I. In vitro activity.
    Pope AJ; Boehm MK; Leach C; Ife RJ; Keeling D; Parsons ME
    Biochem Pharmacol; 1995 Nov; 50(10):1543-9. PubMed ID: 7503755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. By 1023/SK&F 96022: biochemistry of a novel (H+ + K+)-ATPase inhibitor.
    Simon WA; Keeling DJ; Laing SM; Fallowfield C; Taylor AG
    Biochem Pharmacol; 1990 Jun; 39(11):1799-806. PubMed ID: 2160820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SCH 28080 is a lumenally acting, K+-site inhibitor of the gastric (H+ + K+)-ATPase.
    Keeling DJ; Laing SM; Senn-Bilfinger J
    Biochem Pharmacol; 1988 Jun; 37(11):2231-6. PubMed ID: 2837231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Properties of the reversible, K(+)-competitive inhibitor of the gastric (H+/K+)-ATPase, SK&F 97574. II. Pharmacological properties.
    Parsons ME; Rushant B; Rasmussen TC; Leach C; Ife RJ; Postius S; Pope AJ
    Biochem Pharmacol; 1995 Nov; 50(10):1551-6. PubMed ID: 7503756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of (H+ + K+)-ATPase and H+ accumulation in hog gastric membranes by trifluoperazine, verapamil and 8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate.
    Im WB; Blakeman DP; Mendlein J; Sachs G
    Biochim Biophys Acta; 1984 Feb; 770(1):65-72. PubMed ID: 6320882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of a K(+)-competitive inhibitor, a substituted imidazo[1,2a] pyridine, with the phospho- and dephosphoenzyme forms of H+, K(+)-ATPase.
    Mendlein J; Sachs G
    J Biol Chem; 1990 Mar; 265(9):5030-6. PubMed ID: 2156860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of gastric H+/K+-ATPase by substituted imidazo[1,2-a]pyridines.
    Briving C; Andersson BM; Nordberg P; Wallmark B
    Biochim Biophys Acta; 1988 Dec; 946(2):185-92. PubMed ID: 2850003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase.
    Gedda K; Briving C; Svensson K; Maxvall I; Andersson K
    Biochem Pharmacol; 2007 Jan; 73(2):198-205. PubMed ID: 17081503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the mechanism of action of A80915A, a semi-naphthoquinone natural product, as an inhibitor of gastric (H(+)-K+)-ATPase.
    Dantzig AH; Minor PL; Garrigus JL; Fukuda DS; Mynderse JS
    Biochem Pharmacol; 1991 Oct; 42(10):2019-26. PubMed ID: 1683772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pH on the interaction of ligands with the (H+ + K+)-ATPase purified from pig gastric mucosa.
    Ljungström M; Vega FV; Mårdh S
    Biochim Biophys Acta; 1984 Jan; 769(1):220-30. PubMed ID: 6318823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cibenzoline, an ATP-sensitive K(+) channel blocker, binds to the K(+)-binding site from the cytoplasmic side of gastric H(+),K(+)-ATPase.
    Tabuchi Y; Yashiro H; Hoshina S; Asano S; Takeguchi N
    Br J Pharmacol; 2001 Dec; 134(8):1655-62. PubMed ID: 11739241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SCH 28080 is a more selective inhibitor than SCH 32651 at the K+ site of gastric K+/H+-ATPase.
    Beil W; Staar U; Sewing KF
    Eur J Pharmacol; 1987 Jul; 139(3):349-52. PubMed ID: 2822435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the mechanism of action of omeprazole.
    Keeling DJ; Fallowfield C; Milliner KJ; Tingley SK; Ife RJ; Underwood AH
    Biochem Pharmacol; 1985 Aug; 34(16):2967-73. PubMed ID: 2992525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effect of tannic acid on gastric H+,K(+)-ATPase.
    Murakami S; Muramatsu M; Otomo S
    J Nat Prod; 1992 Apr; 55(4):513-6. PubMed ID: 1324983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the mechanism of action of the gastric microsomal (H+ + K+)-ATPase inhibitors SCH 32651 and SCH 28080.
    Scott CK; Sundell E; Castrovilly L
    Biochem Pharmacol; 1987 Jan; 36(1):97-104. PubMed ID: 3026407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ro 18-5364, a potent new inhibitor of the gastric (H+ + K+)-ATPase.
    Sigrist-Nelson K; Krasso A; Müller RK; Fischli AE
    Eur J Biochem; 1987 Jul; 166(2):453-9. PubMed ID: 3038541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The binding of a K+ competitive ligand, 2-methyl,8-(phenylmethoxy)imidazo(1,2-a)pyridine 3-acetonitrile, to the gastric (H+ + K+)-ATPase.
    Keeling DJ; Taylor AG; Schudt C
    J Biol Chem; 1989 Apr; 264(10):5545-51. PubMed ID: 2538422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A newly synthesized pyridine derivative, (Z)-5-methyl-2-[2-(1-naphthyl)ethenyl]-4-piperidinopyridine hydrochloride (AU-1421), as a reversible gastric proton pump inhibitor.
    Hioki Y; Takada J; Hidaka Y; Takeshita H; Hosoi M; Yano M
    Arch Int Pharmacodyn Ther; 1990; 305():32-44. PubMed ID: 2173509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potassium-stimulated ATPase activity and hydrogen transport in gastric microsomal vesicles.
    Lee HC; Breitbart H; Berman M; Forte JG
    Biochim Biophys Acta; 1979 May; 553(1):107-31. PubMed ID: 36910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.